$235M GSK Win Stays, But Fed. Circ. Tells Generics To Relax
A split Federal Circuit panel has once again revived a $235 million verdict against Teva for inducing infringement of GlaxoSmithKline's heart disease drug Coreg, although the panel's revised decision Thursday warned...To view the full article, register now.
Already a subscriber? Click here to view full article